Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Medical Oncology
Non-Hodgkin Lymphoma
Questions discussed in this category
Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?
Is the data sufficient to change your practice?
2 Answers available
Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?
2 Answers available
What subsequent therapies did patients receive after progressing on pritobrutinib in the mantle cell BRUIN trial population?
Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?
2 Answers available
Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?
How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?
2 Answers available
How would you approach treatment for a R/R mantle cell lymphoma patient with a history of autoimmune hepatitis who has progressed on both a covalent and non-covalent BTKi?
1 Answer available
How is pediatric and young adult primary bone lymphoma risk stratified?
NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...
1 Answer available
Should targeted therapies such as Brentuximab or Crizotinib be used in the upfront management of anaplastic large cell lymphoma in a pediatric or AYA patient?
1 Answer available
How do you choose your systemic treatment for primary mediastinal grey zone lymphomas?
Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?
3 Answers available
How would you treat an adolescent or young adult with newly diagnosed hepatosplenic T-cell lymphoma?
1 Answer available
Would you hold rituximab for newly diagnosed B-cell lymphoma if the patient is COVID-19 positive?
What if the patient has a history of confirmed COVID-19 but has since recovered?
1 Answer available
17273
17122
17028
17026
16603
10023
9741
9492
8817
7114
Papers discussed in this category
Blood, 2021 Mar 08
Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with ALK+ALCL: Results of COG Trial ANHL12P1.
J Clin Oncol, 2017 Jan 17
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.
J Clin Oncol, 2023 May 16
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Related Topics in Medical Oncology
Lung Cancer
Breast Cancer
Head and Neck Cancers
Hematologic Malignancies
Radiation Oncology
Gynecologic Cancers
Palliation
Neuro-Oncology
Gastrointestinal Cancers
Genitourinary Cancers